What Factors Are Escalating the Demand Across the Adeno-Associated Virus Vector-Based Gene Therapy Market?

0
0

The increasing prevalence of genetic disorders and the growing adoption of gene therapy have propelled substantial expansion in the AAV vector-based gene therapy domain. According to detailed industry evaluation, the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market was valued at USD 5.718 billion in 2024 and is projected to reach USD 70.67 billion by 2035, exhibiting a CAGR of 25.68% during the forecast period. AAV1, AAV2, AAV5, AAV6, AAV8, and AAV9 serotypes remain among the most sought-after vector platforms globally due to their low immunogenicity, broad tissue tropism, and ability to deliver therapeutic genes for long-term expression. Furthermore, the rising prevalence of genetic disorders, growing focus on personalized medicine, and supportive government initiatives are broadening the adoption base across hematological malignancies, neurological disorders, cardiovascular diseases, ophthalmic diseases, and oncology.

The market is driven by advancements in gene editing technologies and increasing prevalence of genetic disorders. Key players including Spark Therapeutics, Bayer AG, Novartis AG, Bristol-Myers Squibb, GSK, Pfizer Inc., Sarepta Therapeutics, Astellas Pharma Inc., and UniQure N.V. are actively pursuing product innovations and strategic partnerships. Among the leading players, Biogen stands out as a leader with its approved product Zolgensma for spinal muscular atrophy. Novartis is a significant competitor with its Zolgensma gene therapy for spinal muscular atrophy, the first approved treatment of its kind. In Q4 2024, the FDA approved PTC Therapeutics' Kebilidi, the first AAV gene therapy delivered directly into the brain. Do you think AAV gene therapy will eventually become the standard treatment for genetic disorders?

FAQs

What is the current market size of the AAV vector-based gene therapy market?
The market was valued at USD 5.718 billion in 2024 and is projected to reach USD 70.67 billion by 2035, exhibiting a CAGR of 25.68%.

Which segment dominates the AAV gene therapy market?
AAV9 holds the largest market share by vector serotype, while intravenous administration leads by route. Oncology represents the largest disease type segment.

Who are the key players in the AAV gene therapy market?
Key players include Spark Therapeutics, Bayer AG, Novartis AG, Bristol-Myers Squibb, GSK, Pfizer Inc., Sarepta Therapeutics, Astellas Pharma Inc., and UniQure N.V.

#AAVGeneTherapyMarket #GeneTherapy #GeneticDisorders #PrecisionMedicine #Biotechnology

Rechercher
Catégories
Lire la suite
Jeux
Sélénocristallisation : Stratégies et bonus -...
Pouvoirs et Stratégies Bénédiction de la Lune Abyssale : Lune Solide Chaque...
Par Xtameem Xtameem 2026-02-22 09:21:17 0 0
Oportunidade
Automotive High Voltage Cables Market Forecast 2025-2035: How Advanced Cable Technology Is Driving EV Power Transmission and Vehicle Electrification
The global automotive high voltage cables market is experiencing significant growth, driven by...
Par Atharva Parte 2026-08-08 11:23:23 0 0
Jeux
Drill Rig – Red Axis in ZZZ: Effekt, Werte, Build
Die W-Engine Drill Rig – Red Axis in Zenless Zone Zero ist eine speziell für Anton...
Par Xtameem Xtameem 2026-05-21 16:43:50 0 0
Jeux
MMOEXP Monopoly Go:Dice Mastery: Secret Winning Methods for Massive Rewards
Tired of running out of Monopoly Go dice rolls mid-game and missing out on rare rewards?...
Par Damnmy Liop 2026-06-26 02:23:41 0 0
Eventos & Convites
US Luxury Furniture Market Report: Competitive Landscape and Future Growth Forecast
The United States Luxury Furniture Market is witnessing steady expansion, driven by rising...
Par Kadam Radhika 2026-06-26 03:52:11 0 0